Publication date: Sep 10, 2019
Despite the clinical success of cancer immunotherapies, the majority of patients fail to respond or develop resistance through disruption of pathways that promote neo-antigen presentation on MHC I molecules. Here, we conducted a series of unbiased, genome-wide CRISPR/Cas9 screens to identify genes that limit natural killer (NK) cell anti-tumor activity. We identified that genes associated with antigen presentation and/or interferon-γ (IFN-γ) signaling protect tumor cells from NK cell killing. Indeed, Jak1-deficient melanoma cells were sensitized to NK cell killing through attenuated NK cell-derived IFN-γ-driven transcriptional events that regulate MHC I expression. Importantly, tumor cells that became resistant to T cell killing through enrichment of MHC I-deficient clones were highly sensitive to NK cell killing. Taken together, we reveal the genes targeted by tumor cells to drive checkpoint blockade resistance but simultaneously increase their vulnerability to NK cells, unveiling NK cell-based immunotherapies as a strategy to antagonize tumor immune escape.
Freeman, A.J., Vervoort, S.J., Ramsbottom, K.M., Kelly, M.J., Michie, J., Pijpers, L., Johnstone, R.W., Kearney, C.J., and Oliaro, J. Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion. 24062. 2019 Cell Rep (28):11.
|disease||MESH||Tumor Immune Evasion|
- Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
- High-resolution MRI demonstrates that more than ninety percent of small intracranial melanoma metastases develop in close relationship to the leptomeninges.
- Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade.
- Therapeutic blockade of activin-A improves NK cell function and antitumor immunity.
- Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.